Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses

Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses
arcticnovartis

  • Ianalumab (9 mg/kg) plus eltrombopag extended ITP disease control by 45% with patients maintaining disease control 2.8 times longer than with placebo plus eltrombopag1,2
  • 62% of patients treated with ianalumab plus eltrombopag achieved sustained platelet response at six months compared to 39% with placebo plus eltrombopag1,2
/by
1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years

1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years
arcticnovartis

  • Progression-free response stayed consistent across age, BMI, and menopausal status in MONALEESA pooled analysis1
  • KISQALI is only CDK4/6i to demonstrate statistically significant overall survival (OS) in MBC across all Phase III trials2-12
  • New NATALEE 5-year sub-analysis data reinforce sustained reduction in distant disease-free survival in broadest population of EBC patients13
/by